Pacira Pharm Inc (PCRX) 39.04 $PCRX Array (ARRY)

New Post Public Reply Private Reply Replies (0) Message Board

Sep 4, 2016 at 5:15 AM

Pacira Pharm Inc (PCRX) 39.04 $PCRX

Array (ARRY) Oncology Drug Accepted for Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:29AM CDT
Array BioPharma (ARRY) announced that the FDA has accepted a New Drug Application (NDA) for its oncology candidate, binimetinib.
CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33), ARRY: 3.50 (-0.02), NVS: 79.38 (+1.11)

Roche Immuno-oncology Drug Tecentriq Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:22AM CDT
Roche (RHHBY) announced positive results from a phase III study, OAK, on its immuno-oncology drug, Tecentriq.
ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)

Amarin (AMRN) Ends Patient Randomization in Vascepa Study
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:20AM CDT
Amarin (AMRN) announced that it has finished randomizing patients in the phase III REDUCE-IT study on Vascepa (icosapent ethyl).
ANIP: 59.86 (-1.56), AMRN: 2.92 (+0.13), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33)

Pacira Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
GlobeNewswire - Thu Sep 01, 6:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ

CRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Morgan Stanley Global Healthcare Conference at 11:05 a.m. ET on Monday, September 12, 2016, in New York. Mr. Stack is expected to present an overview of the company.
PCRX: 39.04 (-1.33)

Orexigen Stock Up on Commercialization Deal for Contrave
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:11AM CDT
Orexigen (OREX) announced that it has entered into a commercialization and distributorship agreement with Valeant Canada for Contrave in Canada.
OREX: 3.86 (-0.06), VRX: 28.76 (-0.36), ANIP: 59.86 (-1.56), PCRX: 39.04 (-1.33)

Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:16AM CDT
Rigel (RIGL) announced positive data from a phase III study on fostamatinib for the treatment of adult chronic/persistent ITP.
ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33), RIGL: 3.40 (-0.05)

Roche Gets FDA Nod for Emergency Use of Zika Virus Test
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:41AM CDT
Roche Holdings (RHHBY) announced that the FDA has issued an Emergency Use Authorization (EUA) for its LightMix Zika rRT-PCR Test.
ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)

Novartis (NVS) Reports Positive Phase III Results on MS Drug
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:20AM CDT
Novartis AG (NVS) announced positive results from the phase III EXPAND study on its multiple sclerosis candidate BAF312.
TEVA: 51.22 (+0.32), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33), NVS: 79.38 (+1.11)

Mallinckrodt to Divest Nuclear Imaging Business for $690M
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 7:22AM CDT
Mallinckrodt plc (MNK) announced that it has entered into a definitive agreement to sell its Nuclear Imaging business to IBA Molecular for $690 million.
MNK: 72.42 (-3.17), MDCO: 38.31 (-0.66), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)

Cempra's Application for Pneumonia Drug Validated in EU
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 4:02PM CDT
Cempra, Inc. (CEMP) announced that the EMA has validated its MAA for the oral capsule and intravenous (IV) formulations of pipeline candidate solithromycin, for the treatment of community-acquired bacterial pneumonia.
AGN: 235.96 (-1.80), CEMP: 22.11 (-0.18), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)

Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 7:50AM CDT
Novartis AG (NVS) entered into a license agreement with privately held Cyon Therapeutics Inc. for its anti-PCSK9 antibody, LGT-209.
XNCR: 20.35 (-1.08), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33), NVS: 79.38 (+1.11)

Research Report Initiation on Generic Drugs Makers Stocks -- Ironwood Pharma, The Medicines, Carbylan Therapeutics, and Pacira Pharma
PR Newswire - Wed Aug 24, 7:00AM CDT
The global Generic Drugs market is forecasted to grow at a CAGR of 10.53% over the period of 2016 to 2020, according to the 'Global Generic Drugs Market 2016-2020' report released in June 2016. Today, Stock-Callers.com assesses the following companies stocks to see if they are poised for higher returns: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), The Medicines Co. (NASDAQ: MDCO), Carbylan Therapeutics Inc. (NASDAQ: CBYL), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
IRWD: 13.26 (-0.09), MDCO: 38.31 (-0.66), CBYL: 0.49 (+0.01), PCRX: 39.04 (-1.33)

Roche Launches Accu-Chek Blood Glucose Monitoring System
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:47AM CDT
The launch of new systems will help Roche (RHHBY) offset the sales decline in the diabetes care business due to pricing pressure in the U.S. and reimbursement issues
ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)

Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:52AM CDT
Supernus Pharmaceuticals, Inc. (SUPN) announced that the FDA has granted a tentative approval to the company's sNDA for a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.
ANIP: 59.86 (-1.56), SUPN: 21.97 (-0.06), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)

Insys Therapeutics Starts Enrollment in Cannabidiol Trial
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 4:32PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has enrolled the first patient in a phase II trial on its pharmaceutical cannabidiol (CBD) product candidate.
INSY: 14.63 (+0.27), GWPH: 82.73 (+0.45), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)

Valeant Stock Down on Lawsuit by T. Rowe, Alters Credit Loan
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:21AM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has received the requisite lender approval for an amendment to its credit facility which is scheduled to close next week.
VRX: 28.76 (-0.36), TROW: 69.27 (+0.52), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)

Think Out of the Box: Bet on 6 Stocks with Rising P/E
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 8:09AM CDT
Forget undervalued stocks, there is room for upside even in stocks with rising P/E.
ANW: 10.29 (+0.10), MPAA: 29.06 (+0.39), STMP: 99.61 (+0.76), DXYN: 4.68 (-0.16), PCRX: 39.04 (-1.33), HUM: 177.33 (+0.80)

OncoGenex Down on Poor Phase III Data on Lead Cancer Drug
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 8:57AM CDT
Shares of OncoGenex Pharmaceuticals, Inc. (OGXI) were down 41% after the company announced disappointing data from its late-stage trial, AFFINITY, on custirsen in men with metastatic castrate-resistant prostate cancer.
OGXI: 0.53 (-0.02), ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)

Endo (ENDP) Withdraws Label Expansion Filing for Opana ER
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 3:48PM CDT
Endo International (ENDP) announced that after discussions with the FDA the company has decided to withdraw its supplemental new drug application for Opana ER.
ENDP: 19.82 (-0.41), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)

Aurinia (AUPH) Stock Falls on Poor Phase II Lupus Study Data
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 10:08AM CDT
Shares of Aurinia Pharmaceuticals Inc. (AUPH) crashed 55% after the company reported mixed results from a phase IIb study, AURA-LV, on its pipeline candidate, voclosporin.
AUPH: 2.05 (+0.10), ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...